A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study

Autor: Leslie, KK, Sill, MW, Fischer, E, Darcy, KM, Mannel, RS, Tewari, KS, Hanjani, P, Wilken, JA, Baron, AT, Godwin, AK, Schilder, RJ, Singh, M, Maihle, NJ

Publikováno v: Leslie, KK; Sill, MW; Fischer, E; Darcy, KM; Mannel, RS; Tewari, KS; et al.(2013). A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 129(3), 486-494. doi: 10.1016/j.ygyno.2013.02.019. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/9wt4m6w9

Background A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. Methods Women with histologically confirmed persistent/recurrent endometrial cancer were treated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::0ecaf4fe2dd37c0b44d79fbf58c14dd1
http://www.escholarship.org/uc/item/9wt4m6w9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Autor: Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD, Monk, Bradley J, Sill, Michael W, Burger, Robert A, Gray, Heidi J, Buekers, Thomas E, Roman, Lynda D

Publikováno v: Journal of Clinical Oncology; 3/1/2009, Vol. 27 Issue 7, p1069-1074, 6p

Differences in pregnancy desire among pregnant female adolescents at a state-funded family planning clinic.

Autor: Heavey EJ, Moysich KB, Hyland A, Druschel CM, Sill MW

Publikováno v: Journal of Midwifery & Women's Health; Mar/Apr2008, Vol. 53 Issue 2, p130-137, 8p

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Autor: Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI

Publikováno v: Journal of Clinical Oncology; 11/20/2007, Vol. 25 Issue 33, p5165-5171, 7p